Govt Clears Path for Long-Acting HIV Prevention Drug Lenacapavir

The government has cleared the path for the rollout of Lenacapavir, a long-acting HIV prevention medication.

The Ministry of Health, through the Pharmacy and Poisons Board, recommended the registration of Lenacapavir 300 mg tablets and 464 mg injectable solution for pre-exposure prophylaxis (PrEP).

According to the Ministry, the decision followed a thorough review of the drug’s safety, quality, and effectiveness.

Lenacapavir works by targeting critical stages of the HIV lifecycle, preventing the virus from establishing infection.

According to research, its unique long-acting formulation allows it to be administered only twice a year, reducing the need for daily pills and making HIV prevention more convenient for patients.

The injectable form of Lenacapavir is particularly beneficial for individuals who face challenges with daily oral medication, such as pill fatigue or adherence difficulties.

By offering a twice-yearly alternative, the drug aims to improve compliance and expand access to effective HIV prevention.